Penn Medicine Provider
Cardiology
Michael Miller, MD
Accepting new patients
Sees patients age 18 and up
Penn Heart and Vascular Center
Schedule onlineCall 215-615-4949

About me

  • Professor of Medicine (Cardiovascular Medicine) at the Hospital of the University of Pennsylvania

Dr. Michael Miller is a cardiologist at Penn Medicine with a notable interest in preventive cardiology. He specializes in the prevention of heart disease, focusing on risk assessment, lipid (cholesterol and triglyceride) management and lifestyle modification. He is a lecturer for the Perelman School of Medicine Foundations of Culinary Medicine. He has conducted research on the effects of diet and emotional health on inflammation and vascular function with multiple publications on this topic.  Dr. Miller is the author of “Heal Your Heart…” (Penguin Random-House), and co-author of “The American Medical Association Guide to Preventing and Treating Heart Disease (American Medical Association)” and “The Practice of Coronary Disease Prevention” (Lippincott, Williams & Wilkins). 

Recognized by Castle Connolly Top Doctors 2011 - 2024

Education and training

  • Medical School: Rutgers- Robert Wood Johnson Medical School
  • Residency: University of Cincinnati Medical Center
  • Fellowship: Johns Hopkins Hospital
  • Fellowship: Johns Hopkins Hospital

Insurance accepted

My Locations

Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Miller is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Zisman E, Hossain M, Funderburg NT, Christenson R, Jeudy J, Burrowes S, Hays AG, George N, Freeman ML, Rebuck H, Mitchell SE, Miller M, Bagchi S. Association of Lipoprotein (a) with peri-coronary inflammation in persons with and without HIV infection , J Clin Lipidol: 2024

Hegele RA, Ahmad Z, Ashraf A, Baldassarra A, Brown AS, Chait A, Freedman SD, Kohn B, Miller M, Patni N, Soffer DE, Wamng J, Broder MS, Chang E, Uermilov I, Campos C, Gibbs SN Development and Validation of Clinical Criteria to Identify Familial Chylomicronemia Syndrome (FCS) in North America. , J Clin Lipidol : 2024

Burrowes SAB, Zisman E, Fantry LE, Bui Q, Wu A, Sorkin J, Miller M, Bagchi S Changes in Atherosclerotic Cardiovascular Disease Risk Scores in a Predominantly Black Cohort with HIV and Associated Comorbidities: A Preliminary Study. , Cardiology: 2024

Bhatt DL, Bays HE, Miller M, Cain JE 3rd, Wasilewska K, Andrawis NS, Parli T, Feng S, Sterling L, Tseng L, Hartsfield CL, Agollah GD, Mansbach H, Kastelein JJP; ENTRIGUE Principal Investigators. Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. , Nat Med. : 2024

Szarek M, Bhatt DL, Miller M, Brinton E, Jacobson TA, Tardif J-C, Ballantyne CM, Mason RP, Ketchum SB. Pineda AL, Doyle RT, Steg PG, REDUCE-IT Investigators. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. , J Am Coll Cardiol : 2024

Alfaro G, Pendyala J, Sulewski M, Miller M, Vitali C, Cuchel M. Longitudinal analysis of clinical and laboratory biomarkers in a patient with Familial Lecithin: Cholesterol acyltransferase deficiency (FLD) and accelerated eGFR decline: a case study. , . J Clin Lipidol : 2024

Sayah N, Bhatt DL, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Jiao L, Pineda AL, Doyle RT Jr, Tardif JC, Ballantyne CM, Steg PG. Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial. , Eur Heart J. : 2024

Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, Bellows BK, Derington CG, Philip S, Steg G, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. , J Am Heart Assoc, 13: 2024

Miller M Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease. , Curr Opin Cardiol: 2024

Miller M, Bhatt DL, Brinton EA, Jacobson TA, Steg PG, Pineda AL, Ketchum SB, Doyle RT Jr, Tardif JC, Ballantyne CM. Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn , Eur Heart J Open, 3(6): 2023